SARS-CoV-2 Variant Analysis Portfolio Further Expanded

SpeeDx have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The PlexPrime® SARS-CoV-2 Genotyping product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology.

“The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs.

Read the full press release